CA2420768C - Conjugates of defined stoichiometry - Google Patents

Conjugates of defined stoichiometry Download PDF

Info

Publication number
CA2420768C
CA2420768C CA2420768A CA2420768A CA2420768C CA 2420768 C CA2420768 C CA 2420768C CA 2420768 A CA2420768 A CA 2420768A CA 2420768 A CA2420768 A CA 2420768A CA 2420768 C CA2420768 C CA 2420768C
Authority
CA
Canada
Prior art keywords
linker
biomolecule
conjugate
molecular weight
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2420768A
Other languages
English (en)
French (fr)
Other versions
CA2420768A1 (en
Inventor
Eva Hoess
Herbert Andres
Frederic Donie
Rudolf Vogel
Hans-Peter Josel
Rupert Herrmann
Herbert von der Eltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10048417A external-priority patent/DE10048417A1/de
Priority claimed from EP01107491A external-priority patent/EP1245956A1/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2420768A1 publication Critical patent/CA2420768A1/en
Application granted granted Critical
Publication of CA2420768C publication Critical patent/CA2420768C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Catalysts (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
CA2420768A 2000-09-29 2001-09-26 Conjugates of defined stoichiometry Expired - Fee Related CA2420768C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10048417A DE10048417A1 (de) 2000-09-29 2000-09-29 Verbindungen mit verzweigtem Linker
DE10048417.4 2000-09-29
EP01107491A EP1245956A1 (en) 2001-03-29 2001-03-29 Conjugates of defined stoichiometry
EP01107491.1 2001-03-29
PCT/EP2001/011101 WO2002027317A2 (en) 2000-09-29 2001-09-26 Conjugates of defined stoichiometry

Publications (2)

Publication Number Publication Date
CA2420768A1 CA2420768A1 (en) 2002-04-04
CA2420768C true CA2420768C (en) 2012-09-25

Family

ID=26007222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2420768A Expired - Fee Related CA2420768C (en) 2000-09-29 2001-09-26 Conjugates of defined stoichiometry

Country Status (9)

Country Link
US (1) US7897404B2 (enExample)
EP (2) EP1625857A3 (enExample)
JP (1) JP3836429B2 (enExample)
AT (1) ATE313796T1 (enExample)
AU (1) AU2001289923A1 (enExample)
CA (1) CA2420768C (enExample)
DE (1) DE60116146T2 (enExample)
ES (1) ES2254489T3 (enExample)
WO (1) WO2002027317A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
BR112013007614B1 (pt) 2010-10-25 2020-12-29 F. Hoffmann-La Roche Ag método para medir um analito, composição reagente, mistura reagente, uso de uma composição reagente, uso de uma amida de ácido carbônico e kit
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2019175845A2 (en) * 2018-03-15 2019-09-19 Levim Biotech Llp Antibody-biomolecule conjugates linked through multifunctional macromolecule and uses thereof
WO2021055880A1 (en) * 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2493382A (en) * 1948-10-29 1950-01-03 American Cyanamid Co Automatic sample collector
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US5047324A (en) * 1986-12-09 1991-09-10 Miles Inc. Substantially pure enzyme-antibody conjugate preparations
US5554748A (en) * 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
AU657483B2 (en) * 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
CN1114106C (zh) 1994-07-25 2003-07-09 罗切诊断学有限公司 金属螯合物标记的肽及其制备方法
DE59511054D1 (de) 1994-07-25 2006-08-10 Roche Diagnostics Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
DE59507438D1 (de) * 1994-07-25 2000-01-20 Roche Diagnostics Gmbh Hydrophile metallkomplexe
ATE214073T1 (de) 1994-07-25 2002-03-15 Roche Diagnostics Gmbh Hapten-markierte peptide
DE4430972A1 (de) * 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
US5958783A (en) 1994-07-25 1999-09-28 Roche Diagnostics Gmbh Metal complexes with a charged linker
GB9415143D0 (en) 1994-07-27 1994-09-14 Edwards Raymond Glycated haemoglobin assay
CA2258744A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications

Also Published As

Publication number Publication date
EP1364208B1 (en) 2005-12-21
ES2254489T3 (es) 2006-06-16
US7897404B2 (en) 2011-03-01
WO2002027317A2 (en) 2002-04-04
DE60116146T2 (de) 2006-09-14
EP1625857A2 (en) 2006-02-15
AU2001289923A1 (en) 2002-04-08
EP1625857A3 (en) 2008-08-27
DE60116146D1 (de) 2006-01-26
ATE313796T1 (de) 2006-01-15
WO2002027317A3 (en) 2003-09-12
EP1364208A2 (en) 2003-11-26
US20040087501A1 (en) 2004-05-06
JP2004510162A (ja) 2004-04-02
JP3836429B2 (ja) 2006-10-25
CA2420768A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
US6613530B1 (en) Determination of a specific immunoglobulin using multiple antigens
AU594651B2 (en) Immunoassays for protein analytes, particularly HB A1c, involving sample denaturation
US4658022A (en) Binding of antibody reagents to denatured protein analytes
EP0094777B1 (en) Biologically active composition and immunoassay using the same
US4727036A (en) Antibodies for use in determining hemoglobin A1c
US4647654A (en) Peptides useful in preparing hemoglobin A1c immunogens
JPH0926423A (ja) 不活性担体分子に対して複合体形成された被検体もしくはその部分配列を含む免疫アツセイで使用するための合成キヤリブレーター
AU654833B2 (en) The use of pairs of peptides with extremely high specific affinity for one another in the area of in vitro diagnosis
EP1327146B1 (en) Compounds with a branched linker
Kabakoff Chemical aspects of enzyme-immunoassay
JP2575296B2 (ja) イムノアッセイ用合成スタンダード
KR100240514B1 (ko) 멀티머 항원을 사용하는 특이적 면역글로불린의 측정방법
CA2420768C (en) Conjugates of defined stoichiometry
CA2592274C (en) Blocked enzyme-probe complex
EP0338045B1 (en) Solid-phase non-separation enzyme assay
EP1245956A1 (en) Conjugates of defined stoichiometry
JP2003523503A (ja) 疎水性固相に親和性試薬を固定する方法
JP2501960B2 (ja) リガンドを免疫学的に測定するための方法及び試薬
JP3376955B2 (ja) 複合体の分離方法
US5212064A (en) Solid phase non-separation enzyme complementation assay
FI104376B (fi) Hb A1c:lle spesifisiä monoklonaalisia vasta-aineita
JPH0466870A (ja) 新規な標識体及びそれを用いた免疫測定法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190926